• Technology and Data
  • Front End Sales and Marketing
  • Allergy
  • HIV
  • Women's Health
  • Migraine
  • Compounding
  • Continuous Glucose Monitoring
  • Mental Health Awareness
  • Veterinary Pharmacy
  • CBD
  • Infectious Disease
  • Eye Health
  • Digestive Health
  • Biosimilars
  • Influenza
  • Shingles
  • COPD Management
  • Pediatrics
  • Generics
  • Pain Management
  • COVID-19
  • Immunization
  • Oncology
  • Anticoagulants
  • Autoimmune Diseases
  • Dermatology
  • Diabetes
  • Respiratory
  • Heart Health
  • Cardiovascular Clinical Consult

New administration route for MDS therapy


Azacitidine for injection (Vidaza, Pharmion) can now be given intravenously according to the FDA. Instructions for the new route of administration will be added to the prescribing information, which includes the existing subcutaneous route instructions. Now, azacitidine can be infused over 10 to 40 minutes and the dosing will remain the same for both types of administration—75 mg/m2 daily, for seven days, every four weeks. Azacitidine is approved for treatment of the five subtypes of myelodysplastic syndromes (MDS).

To see more Hot off the Press news articles, click here.

To go to the Drug Topics homepage, click here.

Related Videos
Related Content
© 2023 MJH Life Sciences

All rights reserved.